Brief: Dicot Pharma Announces Positive Results From Its Phase 2A Study
23/10/2025 06:19
Oct 23 (Reuters) - Dicot Pharma AB DICOT.ST: DICOT PHARMA ANNOUNCES POSITIVE RESULTS FROM ITS PHASE 2A STUDY LIB-01 EFFECT SUSTAINED AT WEEK 8 WITH STATISTICAL SIGNIFICANCE OUTCOMES DEMONSTRATED CLINICALLY MEANINGFUL IMPROVEMENTS IN ERECTILE FUNCTION AT WEEK 4 Source text: ID:nMFN9dvHtT Further company coverage: DICOT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dicot Pharma AB
See all newsBrief: Dicot Pharma Recruits Cecilia Driving As CFO
Brief: Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S.
Brief: Dicot Pharma Announces Outcome In Oversubscribed Rights Issue
Brief: Dicot Pharma Announces Prelim Rights Issue Outcome
Brief: Dicot Pharma Submits IND Application To FDA